The Predictive and Diagnostic Accuracy of Long Pentraxin-3 in COVID-19 Pneumonia

Overview

Journal Turk J Med Sci

Specialty General Medicine

Date 2020 Dec 14

PMID 33315349

Citations 13

Authors

Ahmed Bilal Genc

Selcuk Yaylaci

Hamad Dheir

Ahmed Cihad Genc

Kubilay Issever

Deniz Cekic

Havva Kocayigit

Erdem Cokluk

Alper Karacan

Mehmet Ramazan Sekeroglu

Hande Toptan Cakar

Ertugrul Guclu

Affiliations

Soon will be listed here.

Abstract

Background/aim: The purpose of this study is to evaluate serum pentraxin-3 (PTX-3) levels in Sars-CoV-2 virus infection (COVID-19) patients and to investigate whether PTX-3 predicts the disease prognosis.

Materials And Methods: This study was conducted on 88 confirmed COVID-19 patients who were hospitalized due to symptomatic pneumonia between April 15 and August 15, 2020. The patients were divided into two groups as survived patients and non-survived patients. Both groups were compared according to demographic features, comorbid conditions and measurement of the PTX-3 and other laboratory parameters of the patients.

Results: Of 88 patients with COVID-19, 59 (67%) were discharged with complete cure and 29 (33%) resulted in death. 46 (52.3%) of the patients were men. PTX-3 median value (IQR) was 3.66 ng/mL (0.9–27.9) in all patients, 3.3 ng/mL (0.9–27.9) in survivors and 3.91 ng/mL (1.9–23.2) in nonsurvivors which was significantly higher (P = 0.045). As a receiver operating characteristic curve analysis the cut-off value of PTX-3 for predicting mortality in patients was 3.73 with 65% sensitivity and 65% specificity (AUC: 0.646, 95% CI: 0.525– 0.767, P = 0.045). Also, we found significant cut-off values with respect to D-dimer, D-dimer/PTX-3, high-sensitivity troponin, high- sensitivity troponin/PTX-3, lymphocyte, PTX-3/lymphocyte, procalcitonin, procalcitonin/PTX-3, CRP, and CRP/PTX-3 (P < 0.05).

Conclusion: In this study, as far as we know, for the first time, we have shown PTX-3 as the new mortality biomarker for COVID-19 disease.

Citing Articles

Acute phase proteins patterns as biomarkers in bacterial infection: Recent insights.

Al Ali A, Darwish W Open Vet J. 2024; 14(10):2539-2550.

PMID: 39545194 PMC: 11560262. DOI: 10.5455/OVJ.2024.v14.i10.4.

Notch4 regulatory T cells and SARS-CoV-2 viremia shape COVID19 survival outcome.

Benamar M, Lai P, Huang C, Chen Q, Oktelik F, Contini P Allergy. 2024; 80(2):557-569.

PMID: 39361431 PMC: 11805648. DOI: 10.1111/all.16333.

Pentraxin-3 (PTX-3) as a potential biomarker for predicting death in hospitalized patients with COVID-19.

Barbosa M, Armstrong A, de Souza C, do Carmo R Virol J. 2024; 21(1):233.

PMID: 39334467 PMC: 11428883. DOI: 10.1186/s12985-024-02501-z.

Serum Pentraxin 3 as Promising Biomarker for the Long-Lasting Inflammatory Response of COVID-19.

Capra A, Crupi L, Panto G, Repici A, Calapai F, Squeri R Int J Mol Sci. 2023; 24(18).

PMID: 37762499 PMC: 10531731. DOI: 10.3390/ijms241814195.

Novel inflammatory biomarkers in the prognosis of COVID-19.

Zhan K, Wang L, Lin H, Fang X, Jia H, Ma X Ther Adv Respir Dis. 2023; 17:17534666231199679.

PMID: 37727063 PMC: 10515606. DOI: 10.1177/17534666231199679.

References

Wiersinga W, Rhodes A, Cheng A, Peacock S, Prescott H . Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020; 324(8):782-793. DOI: 10.1001/jama.2020.12839. View

Introna M, Alles V, Castellano M, Picardi G, De Gioia L, Bottazzai B . Cloning of mouse ptx3, a new member of the pentraxin gene family expressed at extrahepatic sites. Blood. 1996; 87(5):1862-72. View

Uusitalo-Seppala R, Huttunen R, Aittoniemi J, Koskinen P, Leino A, Vahlberg T . Pentraxin 3 (PTX3) is associated with severe sepsis and fatal disease in emergency room patients with suspected infection: a prospective cohort study. PLoS One. 2013; 8(1):e53661. PMC: 3544919. DOI: 10.1371/journal.pone.0053661. View

Tian W, Jiang W, Yao J, Nicholson C, Li R, Sigurslid H . Predictors of mortality in hospitalized COVID-19 patients: A systematic review and meta-analysis. J Med Virol. 2020; 92(10):1875-1883. PMC: 7280666. DOI: 10.1002/jmv.26050. View

Ryoo S, Han K, Ahn S, Shin T, Hwang S, Chung S . The usefulness of C-reactive protein and procalcitonin to predict prognosis in septic shock patients: A multicenter prospective registry-based observational study. Sci Rep. 2019; 9(1):6579. PMC: 6488613. DOI: 10.1038/s41598-019-42972-7. View

Low G, Gan S, Zainal N, Naidu K, Amin-Nordin S, Khoo C . The predictive and diagnostic accuracy of vascular endothelial growth factor and pentraxin-3 in severe dengue. Pathog Glob Health. 2018; 112(6):334-341. PMC: 6381533. DOI: 10.1080/20477724.2018.1516417. View

Bottazzi B, Doni A, Garlanda C, Mantovani A . An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu Rev Immunol. 2009; 28:157-83. DOI: 10.1146/annurev-immunol-030409-101305. View

Koozi H, Lengquist M, Frigyesi A . C-reactive protein as a prognostic factor in intensive care admissions for sepsis: A Swedish multicenter study. J Crit Care. 2019; 56:73-79. DOI: 10.1016/j.jcrc.2019.12.009. View

Wang L . C-reactive protein levels in the early stage of COVID-19. Med Mal Infect. 2020; 50(4):332-334. PMC: 7146693. DOI: 10.1016/j.medmal.2020.03.007. View

10.

Rothenburger M, Markewitz A, Lenz T, Kaulbach H, Marohl K, Kuhlmann W . Detection of acute phase response and infection. The role of procalcitonin and C-reactive protein. Clin Chem Lab Med. 1999; 37(3):275-9. DOI: 10.1515/CCLM.1999.048. View

11.

The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team . The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) - China, 2020. China CDC Wkly. 2021; 2(8):113-122. PMC: 8392929. View

12.

Messner C, Demichev V, Wendisch D, Michalick L, White M, Freiwald A . Ultra-High-Throughput Clinical Proteomics Reveals Classifiers of COVID-19 Infection. Cell Syst. 2020; 11(1):11-24.e4. PMC: 7264033. DOI: 10.1016/j.cels.2020.05.012. View

13.

Mantovani A, Garlanda C, Doni A, Bottazzi B . Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3. J Clin Immunol. 2007; 28(1):1-13. DOI: 10.1007/s10875-007-9126-7. View

14.

Huang I, Pranata R, Lim M, Oehadian A, Alisjahbana B . C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. Ther Adv Respir Dis. 2020; 14:1753466620937175. PMC: 7336828. DOI: 10.1177/1753466620937175. View

15.

He X, Han B, Liu M . Long pentraxin 3 in pulmonary infection and acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2007; 292(5):L1039-49. DOI: 10.1152/ajplung.00490.2006. View

16.

Tian F, Li H, Wang L, Li B, Maidinaimu Aibibula , Zhao H . The diagnostic value of serum C-reactive protein, procalcitonin, interleukin-6 and lactate dehydrogenase in patients with severe acute pancreatitis. Clin Chim Acta. 2020; 510:665-670. DOI: 10.1016/j.cca.2020.08.029. View

17.

Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T . Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci. 2020; 57(6):389-399. PMC: 7284147. DOI: 10.1080/10408363.2020.1770685. View

18.

Bethell D, Flobbe K, Cao X, Day N, Pham T, Buurman W . Pathophysiologic and prognostic role of cytokines in dengue hemorrhagic fever. J Infect Dis. 1998; 177(3):778-82. DOI: 10.1086/517807. View

19.

Song J, Park D, Moon S, Cho H, Park J, Seok H . Diagnostic and prognostic value of interleukin-6, pentraxin 3, and procalcitonin levels among sepsis and septic shock patients: a prospective controlled study according to the Sepsis-3 definitions. BMC Infect Dis. 2019; 19(1):968. PMC: 6852730. DOI: 10.1186/s12879-019-4618-7. View